CPC A61K 38/193 (2013.01) [A61K 38/2278 (2013.01); G01N 33/505 (2013.01); G01N 33/6896 (2013.01); G01N 33/942 (2013.01); G01N 2800/52 (2013.01)] | 4 Claims |
1. A method of determining the efficacy of a Parkinson's disease treatment, said method comprising:
a) administering the Parkinson's disease treatment to a subject having Parkinson's disease, wherein said Parkinson's disease treatment is sargramostim; and
b) measuring the amount of at least one metabolite of the tryptophan pathway in a biological sample obtained from the subject after step a),
wherein at least one of the metabolites measured in step b) is L-kynurenine, quinolinic acid, or serotonin, and
wherein an increase in the amount of L-kynurenine or quinolinic acid after administration of the Parkinson's disease treatment indicates the Parkinson's disease treatment is effective against Parkinson's disease or wherein a decrease in the amount of serotonin after administration of the Parkinson's disease treatment indicates the Parkinson's disease treatment is effective against Parkinson's disease; and
c) treating said subject with sargramostim when the Parkinson's disease treatment is effective against Parkinson's disease.
|